Crystal's Coder Hub🧬 Modifier -JZ — Zero Drug Amount Discarded
Official CMS Definition
Modifier -JZ — Zero drug amount discarded/not administered to any patient.
🔑 Key Concept
Modifier -JZ is a HCPCS Level II modifier introduced in the 2023 Medicare Physician Fee Schedule Final Rule (Nov. 2022) to attest that no drug was discarded or wasted from a single-dose container or single-use package during administration to a Medicare Part B patient. [^1]
It works as the companion modifier to -JW (Drug amount discarded/not administered to any patient). Together, these two modifiers give CMS a complete picture of how single-dose vials are used — whether the full amount was administered (-JZ) or some portion was wasted (-JW). [^2]
Mandatory as of October 1, 2023
-JZ was voluntary from January 1, 2023 through June 30, 2023. It became required effective July 1, 2023 (with full enforcement mandatory by October 1, 2023) for all separately payable Part B drugs billed from single-dose containers or single-use packages where no drug was discarded. Claims missing the required modifier are subject to denial. [^3]
📌 Why CMS Created -JZ
Prior to 2023, only -JW existed to track drug wastage. CMS discovered there was very low utilization of -JW, raising compliance concerns — if providers weren’t reporting waste, were they properly discarding unused drug? Were they pooling vials across patients?
By creating -JZ, CMS now requires an affirmative attestation on every single-dose drug claim: either waste occurred (-JW) or it did not (-JZ). The combined data feeds into the Inflation Reduction Act’s discarded drug refund calculation, requiring manufacturers to pay rebates when drugs are frequently wasted. [^4]
Think of it this way
✅ When to Use -JZ
- The drug was administered from a single-dose container or single-use package
- The entire amount drawn was administered to the patient — no discarded remainder
- The administered dose equals the total amount in the vial or the dose given is less than the billing unit (see fractional billing note below)
- The drug HCPCS code is separately payable under Part B (OPPS Status Indicator G or K for institutional; standard separately payable drug codes for professional)
- Billing occurs on a CMS-1500 (professional) or CMS-1450/UB-04 (institutional/outpatient)
Fractional Billing Units
❌ When NOT to Use -JZ
- Multi-dose vials — -JZ and -JW do not apply to multi-dose containers; only single-dose/single-use containers are in scope
- Drug is packaged into the procedure payment (OPPS Status Indicator N) — no separate drug billing required
- Drug was billed under Part D, not Part B
- Waste did occur — use -JW on a separate claim line instead
- Service is provided in a hospital inpatient setting where drug costs are bundled into the DRG (facility side); profee drug administration claims may still apply
🔁 JZ vs. JW — Side-by-Side
| Feature | -JW | -JZ |
|---|---|---|
| Meaning | Drug was discarded/wasted | No drug was discarded |
| Claim lines needed | Two (administered + waste) | One |
| Units reported | Wasted units on line 2 | Administered units only |
| Introduced | January 1, 2017 | January 1, 2023 |
| Mandatory | Yes (since 2017) | Yes (since July 1, 2023) |
| Vial type | Single-dose containers only | Single-dose containers only |
| Payment for waste | Yes — Medicare pays waste | N/A — no waste occurred |
💊 Common Drug Codes Used with -JZ
These are frequently encountered HCPCS drug codes where -JZ applies when no drug is wasted. Note: the specific HCPCS drug codes below are examples of separately payable single-dose drugs — always verify the FDA label designates them as single-dose before appending -JZ.
| Drug | HCPCS Code | Common Specialty |
|---|---|---|
| Aflibercept (Eylea) | J0178 | Ophthalmology |
| Ranibizumab (Lucentis) | J2778 | Ophthalmology |
| Bevacizumab (Avastin) — compounded | J9035 | Ophthalmology / Oncology |
| Faricimab (Vabysmo) | J0180 | Ophthalmology |
| Pembrolizumab (Keytruda) | J9271 | Oncology |
| Nivolumab (Opdivo) | J9299 | Oncology |
| Dexamethasone implant (Ozurdex) | J7312 | Ophthalmology |
| Fluocinolone implant (Iluvien/Yutiq) | J7313 | Ophthalmology |
| Pertuzumab (Perjeta) | J9306 | Oncology |
Always Verify FDA Labeling
📋 Usage Examples
Example 1 — Ophthalmology: Intravitreal Injection, Full Vial Used 👁️
A retinal specialist administers aflibercept 2 mg intravitreal injection to a Medicare patient for wet AMD. The vial is labeled as a single-dose container. The physician draws the full dose and administers it entirely — nothing is wasted.
Claim submission (one line):
- J0178--JZ — Aflibercept, 1 mg; 2 units administered (= 2 mg), zero discarded
Medicare Part B reimburses at ASP + 6% for the 2 units. The -JZ attests no waste occurred. No second claim line needed. Documentation should reflect: drug name, lot number, dose administered, and that the full vial contents were used. [^6]
Example 2 — Ophthalmology: Drug Implant with No Discardable Remainder
A patient receives a dexamethasone intravitreal implant (Ozurdex) for macular edema secondary to H35.81 (Macular cyst, hole, or pseudohole) — (parent: H35.8). The implant is a single-use device with no discardable drug component.
Claim submission:
- J7312--JZ — Dexamethasone, intravitreal implant; 1 unit, zero discarded
- 67028 — Intravitreal injection of a pharmacologic agent
The Ozurdex implant carries OPPS Status Indicator K2 in the ASC setting and should always be reported with -JZ, as there is no discard possible with the implant delivery system. [^7]
Example 3 — Oncology Infusion: Full Vial Administered
A Medicare patient with non-small cell lung cancer presents for their scheduled pembrolizumab infusion. The pharmacy prepares the dose from a single-dose vial. The weight-based dose exactly matches the vial content — no waste.
Claim submission (one line):
- J9271--JZ — Pembrolizumab, 1 mg; [X units] administered, zero discarded
- 96413 — Chemotherapy administration, intravenous infusion; up to 1 hour
Weight-Based Dosing Tip
For oncology drugs dosed by weight (mg/kg), the prepared dose rarely equals a perfect vial amount. If there IS leftover drug in the vial that must be discarded, shift to -JW on a second line. Confirm with the pharmacy record what was actually drawn and whether any remainder was discarded vs. retained (multi-dose vials only).
Example 4 — Fractional Billing Unit Scenario
A Medicare patient receives 1.5 mg of a drug where the billing unit is 1 mg. The provider administers 1.5 units worth of drug — but Medicare does not accept fractional billing units. The provider bills 2 full units.
Claim submission:
- [Drug HCPCS]--JZ — 2 units billed (full billing units); JZ attests no drug was discarded — the 0.5 unit overage is a billing unit structure issue, not actual waste
Do Not Use -JW Here
Example 5 — Institutional / Outpatient Hospital Claim (CMS-1450)
A hospital outpatient infusion center administers nivolumab to a Medicare patient. The drug is billed on the UB-04 with Revenue Code 0636. The vial is single-dose. Full vial administered, no waste.
Claim submission:
- Revenue Code 0636
- J9299--JZ — Nivolumab, 1 mg; [X units]; OPPS Status Indicator K
For institutional claims, -JZ must appear for drugs with OPPS status indicator G (Pass-Through) or K (Non-pass-through separately payable). Drugs with status indicator N (packaged) do not require the modifier because they are not billed separately. [^4]
⚠️ Inpatient / Profee Considerations
As an inpatient profee coder, -JZ is most relevant when:
- Physicians buy and bill drugs directly (e.g., injecting physician billing their own drug supply) — Part B drug billing
- Outpatient hospital profee claims are billed on the CMS-1500 for drugs separately administered by the physician in an outpatient setting
- You are reviewing OPPS claims for outpatient encounters and verifying drug line accuracy
Inpatient DRG Note
Drugs administered during a Medicare Part A inpatient stay are bundled into the DRG — -JZ and -JW do not apply to inpatient facility claims. These modifiers are strictly Part B and outpatient in scope. Profee physician services during inpatient stays bill drug administration codes (e.g., 96365, 96372) without drug supply codes, as the facility bills the drug. [^3]
📝 Documentation Requirements
To support -JZ on a claim, the medical record should contain:
- Drug name, NDC number, lot number, and expiration date
- Dose ordered and dose administered (in mg or mcg)
- Total vial contents as labeled by the FDA
- Route of administration
- Date and time of administration
- Attestation or clinical note confirming the full amount was administered and no drug was discarded
- Any pharmacy preparation records if applicable
Audit Risk